Kyle Amber to Immunosuppressive Agents
This is a "connection" page, showing publications Kyle Amber has written about Immunosuppressive Agents.
Connection Strength
1.840
-
Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs. 2018 Oct; 78(15):1527-1548.
Score: 0.579
-
Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatol. 2017 11 01; 153(11):1137-1141.
Score: 0.544
-
Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions". Int J Dermatol. 2017 01; 56(1):e4-e5.
Score: 0.503
-
A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. Am J Clin Dermatol. 2020 Aug; 21(4):557-565.
Score: 0.164
-
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. 2023 03 30; 188(4):499-505.
Score: 0.049